Research Reports

Key takeaways

Dr. Jeymi Tambiah appointed as new Chief Medical Officer, bringing over 18 years of clinical development and regulatory strategy experience.

Dr. Mark Kowalski is retiring as CMO but will support the company as a senior consultant during the transition period.

CEO Dr. James A. Helliwell highlighted Dr. Tambiah's experience as crucial for advancing the EP-104GI program in Eosinophilic Esophagitis.

Dr. Tambiah's background includes leadership in immunology programs and late-stage clinical and regulatory milestones.

EP-104GI is currently in a Phase 1b/2 trial (RESOLVE) for Eosinophilic Esophagitis, representing a key development catalyst.

Full analysis

Eupraxia Pharmaceuticals announced a leadership transition in its medical division with the appointment of Dr. Jeymi Tambiah as Chief Medical Officer, succeeding Dr. Mark Kowalski who is retiring. Dr. Tambiah brings over 18 years of experience in clinical development, medical and regulatory strategy, and product commercialization. He is a Board Certified Cardiothoracic Surgeon and has previously led immunology programs through late-stage clinical and regulatory milestones. CEO Dr. James A. Helliwell emphasized that Dr. Tambiah's expertise will be instrumental in advancing the company's Gastroenterology pipeline, specifically the EP-104GI program for Eosinophilic Esophagitis (EoE), which is currently in the Phase 1b/2 RESOLVE trial. Dr. Kowalski will remain involved as a senior consultant to ensure a smooth transition.

EPRX · Eupraxia Pharmaceuticals Inc.

Summary

Key takeaways

Full analysis